Collin Gage currently serves as Chief Executive Officer and Director for ARMR Sciences, Inc. After being personally impacted by addiction and overdose, Collin decided to spend his career challenging the status quo by developing innovative new solutions. During this process, he and his partners created ARMR with the mission of providing preventative and protective solutions for the addiction and overdose epidemic. Prior to founding ARMR, Collin was the Senior Vice President of Corporate Development and Investor Relations at Mind Medicine Inc. (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on pioneering addiction and mental health treatments. During his tenure at MindMed, he managed firm-wide capital markets strategy, laying the foundation for the company to go on to raise more than $250 million to support late-stage clinical trials. This eventually led to MindMed receiving Breakthrough Therapy Designation from the Food & Drug Administration (FDA) for its Phase 2b clinical trial. Before MindMed, Collin was responsible for researching investing in innovative early-stage startups at a private family office. In his role, he worked with several venture-backed startups to guide them through complex financial strategies in private and public capital markets. Before this role, Collin worked as a Consultant for Tesla, Inc. (NASDAQ: TSLA), where he was responsible for identifying and executing emerging market growth strategies. Collin began his career as a consultant at Point72 Asset Management, a global multi-strategy asset manager.